2022
DOI: 10.1016/s1473-3099(22)00416-9
|View full text |Cite|
|
Sign up to set email alerts
|

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
26
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 14 publications
3
26
0
Order By: Relevance
“…We note that this relationship is predominately driven by observations of one study, where the longest time course of protection was collected (i.e. the relationship is only significant when the Herman et al 14 data is included, Table S3). Fitting a logistic dose-response relationship to this data, we estimated a peak efficacy of 91% (95% CI: 86 – 99%), and concentration for 50% of efficacy of 939-fold in vitro IC50 (95% CI: 135 – 2073) (Table S4).…”
Section: Resultsmentioning
confidence: 96%
See 3 more Smart Citations
“…We note that this relationship is predominately driven by observations of one study, where the longest time course of protection was collected (i.e. the relationship is only significant when the Herman et al 14 data is included, Table S3). Fitting a logistic dose-response relationship to this data, we estimated a peak efficacy of 91% (95% CI: 86 – 99%), and concentration for 50% of efficacy of 939-fold in vitro IC50 (95% CI: 135 – 2073) (Table S4).…”
Section: Resultsmentioning
confidence: 96%
“…Another factor affecting our analysis is the different mode of delivery of the monoclonal antibodies. Casirivimab/imdevimab was administered subcutaneously in the Isa 5 , O’Brien 6 and Herman 14 studies, whereas tixagevimab/cilgavimab was administered intramuscularly in the Levin study 4 . Plasma antibody concentrations had much slower increases following intramuscular administration of tixagevimab/cilgavimab compared with subcutaneous administration of casirivimab/imdevimab, and thus it is possible that there is a delay until protective antibody concentrations are achieved (Figure 1).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Moreover, although accurate information regarding the pros and cons of vaccines is not currently available, various COVID-19 vaccines have shown good efficacy in preventing SARS-CoV-2 infection and reducing disease severity and mortality ( 21 23 ). The anti-SARS-CoV-2 monoclonal antibodies demonstrated positive effects in pre-exposure prophylaxis against susceptible variants ( 24 ), prevention of progression to severe COVID-19 ( 25 ), and reduction of patient mortality ( 26 ). In addition, because it can recognize the receptor binding domain (RBD) or other SARS-CoV-2 receptors, nanobodies have also been developed to detect the spike proteins of SARS-CoV-2 variants including Omicron ( 27 ), and show the potential of neutralizing SARS-CoV-2 variants ( 28 31 ).…”
Section: Introductionmentioning
confidence: 99%